Review article

Cardiovascular effects of oral medications in the treatment of type 2 diabetes

Saša Magaš ; Bjelovar General Hospital, Bjelovar, Croatia

Abstract

Diabetes mellitus (DM) is in rise worldwide. More than 90% of patients suffer from type 2 DM. The majority of patients suffering from type 2 DM are treated with oral medications. In addition to lowering glycemia, the medications for treatment of DM may either have direct effects on the cardiovascular system or the effects on cardiovascular risk factors. The administration of sulfonylurea and thiazolidinedione attracts the most attention because of the potential negative impact on the in- creased risk of death or heart failure. On the other hand, better pleiotropic and metabolic effects of pioglitazone and metformin are known. Repaglinide administered with metformin may increase the cardiovascular risk, although it has a positive effect on lowering inflammatory cytokines. Dipeptidyl peptidase-4 inhibitors do not increase cardiovascular risks, and they improve metabolic variables.

Keywords

oral hypoglycemics; cardiovascular risks; sulfonylurea; metformin; thiazolidinediones

Hrčak ID:

112562

URI

https://hrcak.srce.hr/112562

Publication date:

2.10.2013.

Article data in other languages: croatian

Visits: 2.015 *